Cancer cells that are HER2 negative may grow more slowly and are less likely to recur (come back) or spread to other parts of the body than cancer cells that have a large amount of HER2 on their surface. Cancers that may be HER2 negative include breast, bladder, ovarian, pancreatic, and stomach cancers. People with HER2-negative breast cancer may need surgery, chemotherapy, radiation therapy, bisphosphonates, or a combination of these treatments. According to the latest estimates, the global her-2 negative breast cancer market is set to achieve an incremental growth of USD 7.6 billion, accelerating at a CAGR of almost 9.5% during the forecast period 2023-2029.

The report covers market size and growth, segmentation, regional breakdowns, competitive landscape, trends and strategies for global her-2 negative breast cancer market. It presents a quantitative analysis of the market to enable stakeholders to capitalize on the prevailing market opportunities. The report also identifies top segments for opportunities and strategies based on market trends and leading competitors’ approaches.

This industry report offers market estimates and forecasts of the global market, followed by a detailed analysis of the type of treatment, and region. The global market for her-2 negative breast cancer can be segmented by type of treatment: chemotherapy, hormonal therapy, radiation, others. The chemotherapy segment held the largest share of the global her-2 negative breast cancer market in 2022 and is anticipated to hold its share during the forecast period. Her-2 negative breast cancer market is further segmented by region: North America, Europe, Asia-Pacific, MEA (Middle East and Africa), Latin America. Globally, North America made up the largest share of the her-2 negative breast cancer market.

Market Segmentation
By type of treatment: chemotherapy, hormonal therapy, radiation, others
By region: North America, Europe, Asia-Pacific, MEA (Middle East and Africa), Latin America

The report also provides a detailed analysis of several leading her-2 negative breast cancer market vendors that include AstraZeneca plc, Bristol-myers Squibb Company, Chipscreen Biosciences, Ltd., Eisai Co., Ltd., Eli Lilly and Company, F. Hoffmann-La Roche AG, GlaxoSmithKline plc, Merck & Co. Inc., Novartis AG, Pfizer Inc., Radius Health, Inc., Syndax Pharmaceuticals Inc., among others. In this report, key players and their strategies are thoroughly analyzed to understand the competitive outlook of the market.
*REQUEST FREE SAMPLE TO GET A COMPLETE LIST OF COMPANIES

Scope of the Report
• To analyze and forecast the market size of the global her-2 negative breast cancer market.
• To classify and forecast the global her-2 negative breast cancer market based on type of treatment, region.
• To identify drivers and challenges for the global her-2 negative breast cancer market.
• To examine competitive developments such as mergers & acquisitions, agreements, collaborations and partnerships, etc., in the global her-2 negative breast cancer market.
• To identify and analyze the profile of leading players operating in the global her-2 negative breast cancer market.

Why Choose This Report
• Gain a reliable outlook of the global her-2 negative breast cancer market forecasts from 2023 to 2029 across scenarios.
• Identify growth segments for investment.
• Stay ahead of competitors through company profiles and market data.
• The market estimate for ease of analysis across scenarios in Excel format.
• Strategy consulting and research support for three months.
• Print authentication provided for the single-user license.